Although a defined clinical phenotype is used to distinguish Alzheimer's disease (AD) from other late-life dementias, the accuracy of antemortem tests for the diagnosis of AD are imperfect. Ultimately, AD is defined most securely when the clinical phenotype is coupled with the postmortem detection of specific brain lesions considered to be """"""""pathological signatures"""""""" of AD. Uncertainty about the antemortem diagnosis of AD is likely to impede efforts to develop and test potentially useful therapies. Indeed, as many as 20% of elderly patients with a dementia ascribed to AD will fail to exhibit postmortem evidence of the neurofibrillary tangles (NFTs) and senile plaques (SPs) identified as hallmarks of AD. This subset of elderly patients with an AD-like dementia, but no AD pathology, may exhibit lesions characteristic of Pick's disease, diffuse Lewy body (LB) disease (DLBD) or other neurodegenerative diseases associated with profound cognitive dysfunction. The consistent assignment of elderly demented patients followed by the Clinical Core (Core B) of this ADCC to 1 of several diagnostic categories (e.g. AD, DLBD) is central to the mission of this ADCC. Hence, the goal of the Neuropathology Core (Core C) of this ADCC is to obtain and thoroughly characterize postmortem tissues from all deceased ADCC patients for whom permission for an autopsy is obtained. Complete autopsies will be performed and objective criteria will be used to sort the cases into well defined diagnostic categories. Further, all of the vital information on this case material (e.g. age of the patient, diagnosis, postmortem interval, means of tissue denaturation, tissue recipients, etc.) will be recorded in an electronic data base for correlation with clinical data obtained on these patients in Core B. Finally, Core C will serve as a resource to other investigators in this ADCC, a related Program Project (""""""""Molecular Substrates Of Aging & Neuron Death"""""""", P01 AG-09215) on AD and idiopathic Parkinson's disease (PD), and new research projects on AD stimulated by the presence of this ADCC at the University of Pennsylvania.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Center Core Grants (P30)
Project #
5P30AG010124-08
Application #
6267520
Study Section
Project Start
1998-07-15
Project End
1999-06-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
8
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Goldman, Jennifer G; Andrews, Howard; Amara, Amy et al. (2018) Cerebrospinal fluid, plasma, and saliva in the BioFIND study: Relationships among biomarkers and Parkinson's disease Features. Mov Disord 33:282-288
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95
Stites, Shana D; Rubright, Jonathan D; Karlawish, Jason (2018) What features of stigma do the public most commonly attribute to Alzheimer's disease dementia? Results of a survey of the U.S. general public. Alzheimers Dement 14:925-932
Seo, Sang Won; Thibodeau, Marie-Pierre; Perry, David C et al. (2018) Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. Neurology 90:e1047-e1056
Shi, Min; Tang, Lu; Toledo, Jon B et al. (2018) Cerebrospinal fluid ?-synuclein contributes to the differential diagnosis of Alzheimer's disease. Alzheimers Dement 14:1052-1062
Wang, Qi; Guo, Lei; Thompson, Paul M et al. (2018) The Added Value of Diffusion-Weighted MRI-Derived Structural Connectome in Evaluating Mild Cognitive Impairment: A Multi-Cohort Validation1. J Alzheimers Dis 64:149-169
Kirson, Noam Y; Scott Andrews, J; Desai, Urvi et al. (2018) Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease. J Alzheimers Dis 61:295-307
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Zee, Jarcy; Xie, Sharon X (2018) The Kaplan-Meier Method for Estimating and Comparing Proportions in a Randomized Controlled Trial with Dropouts. Biostat Epidemiol 2:23-33

Showing the most recent 10 out of 720 publications